[Clinical evaluation of Tegafur suppository in the treatment of uterine cancer--with special reference to the drug concentration in the blood, secretion from the pelvic dead space, and tissues of female genital organs].
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism*; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000378:metabolism; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D010388:Pelvis / Q000378:metabolism; D013488:Suppositories; D005641:Tegafur / Q000008:administration & dosage / Q000378:metabolism*; D014018:Tissue Distribution; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism*
D000970:Antineoplastic Agents; D013488:Suppositories; D005641:Tegafur; D005472:Fluorouracil